Abstract
The controlled-release market was worth nearly US$21 billion globally in 2008.
The sector is dominated by the launch of oral controlled-release formulations
in key therapeutic areas such as the central nervous system, cardiovascular,
metabolic and respiratory diseases. The growth of controlled-release delivery
continues to be fuelled by line extensions helping to offset the impact of
generic erosion. We estimate there are around 60 approved controlled-release
products which will generate global sales of over US$21.5 billion in 2009,
peaking at around US$29.5 billion in 2017 as products mature and face patent
expiration leading to a decline in mature product sales to US$28.9 billion by
2018. In addition, we forecast that controlled-release products in
development from 17 key companies could generate additional sales of over
US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved
delivery systems, have been an important tool for pharmaceutical companies to
protect their branded franchises from the ever increasing and competitive
generic market. These formulations play a critical role in establishing a
balanced portfolio of solid dosage products and may lead to enhanced efficacy
and improved patient compliance. This leads to reductions in patient costs
and extending product life-cycle management for both branded and generic
pharmaceuticals.
In the past, pharmaceutical companies have tended to develop
controlled-release formulations as immediate-release counterparts near patent
expiration. This trend is reversing and companies are developing
controlled-release formulations earlier in the product life-cycle and often
launching multiple formulations (immediate release, controlled release/
modified release, and delayed release) in parallel to expand the potential
addressable patient population and gain a significant share of competitive
market places.
This report answers key questions...
- Who will have launched novel products by 2018 and what technologies could
they be using?
- Can market leaders such as ALZA and Elan maintain their status in
controlled release in the face of growing competition?
- What obstacles must companies overcome to achieve full market potential?
- What strategies are proving most productive and for which companies?
- What will the product/company landscape look like in 2018?
This report is part of a major new 4-volume strategic analysis
Focusing on the sectors that are driving growth
- VOLUME I: CONTROLLED- RELEASE
- VOLUME II: NANOTECHNOLOGY
- VOLUME III: NUCLEIC ACID DELIVERY
- VOLUME IV: TARGETED DELIVERY
| 
View Cart
